No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
FBLG FibroBiologics
- 4.250
- +0.110+2.66%
Trading Jul 3 09:58 ET
139.06MMarket Cap-6168P/E (TTM)
4.270High4.090Low4.54KVolume4.090Open4.140Pre Close18.95KTurnover0.02%Turnover RatioLossP/E (Static)32.72MShares55.00052wk High-36.02P/B96.52MFloat Cap3.90052wk Low--Dividend TTM22.71MShs Float55.000Historical High--Div YieldTTM4.35%Amplitude3.900Historical Low4.178Avg Price1Lot Size
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | FibroBiologics Highlights Preliminary Proof-Of-Concept For Novel Artificial Thymus Organoid Technology
Express News | Fibrobiologics Announces Preliminary Proof of Concept for Novel Artificial Thymus Organoid Technology
FibroBiologics Files for 16.02M Shares of Common Stock by Selling Shareholder
Express News | FibroBiologics Files Prospectus Relates To Resale Of Up To 16M Shares Of Common Stock By GEM
Express News | Fibrobiologics Inc Files Rospectus Relates to Resale of up to 16 Mln Shares of Common Stock by Gem - SEC Filing
Express News | FibroBiologics To Join Russell 2000 Index; Effective July 1 Following Annual Reconstitution
Comments
$FibroBiologics(FBLG.US$
FibroBiologics Announces Preliminary Proof of Concept for Novel Artificial Thymus Organoid Technology
FibroBiologics (Nasdaq: FBLG), a clinical-stage biotech company, has developed a novel artificial thymus organoid capable of restoring immune function in severe combined immunodeficiency (SCID) mouse models. This organoid is made from fibroblasts and thymus-derived cells and can produce mature and diverse T cells, including CD4, CD8, and regulatory T cells. The comp...
FibroBiologics Announces Preliminary Proof of Concept for Novel Artificial Thymus Organoid Technology
FibroBiologics (Nasdaq: FBLG), a clinical-stage biotech company, has developed a novel artificial thymus organoid capable of restoring immune function in severe combined immunodeficiency (SCID) mouse models. This organoid is made from fibroblasts and thymus-derived cells and can produce mature and diverse T cells, including CD4, CD8, and regulatory T cells. The comp...
$FibroBiologics(FBLG.US$ why the spike?
Ruben Garcia's appointment as General Counsel is a key milestone for FibroBiologics. His expertise in public company reporting, corporate governance, healthcare compliance, and strategic transactions is set to boost the company's leadership and efficiency, and aid its clinical and pre-clinical pipelines.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
